These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30471053)

  • 61. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal.
    Schroeder PR; Haugen BR; Pacini F; Reiners C; Schlumberger M; Sherman SI; Cooper DS; Schuff KG; Braverman LE; Skarulis MC; Davies TF; Mazzaferri EL; Daniels GH; Ross DS; Luster M; Samuels MH; Weintraub BD; Ridgway EC; Ladenson PW
    J Clin Endocrinol Metab; 2006 Mar; 91(3):878-84. PubMed ID: 16394083
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients.
    Tala Jury HP; Castagna MG; Fioravanti C; Cipri C; Brianzoni E; Pacini F
    J Clin Endocrinol Metab; 2010 Jan; 95(1):230-7. PubMed ID: 19858316
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals.
    Vallejo JA; Muros MA
    Rev Esp Med Nucl Imagen Mol; 2017; 36(6):362-370. PubMed ID: 28539216
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Association Between Pregnancy Outcomes and Radioactive Iodine Treatment After Thyroidectomy Among Women With Thyroid Cancer.
    Kim HO; Lee K; Lee SM; Seo GH
    JAMA Intern Med; 2020 Jan; 180(1):54-61. PubMed ID: 31633736
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.
    Ozkan C; Akturk M; Altinova AE; Cerit ET; Gulbahar O; Yalcin MM; Cakir N; Balos Toruner F
    Endocr J; 2015; 62(12):1091-9. PubMed ID: 26490048
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease.
    Wolfson RM; Rachinsky I; Morrison D; Driedger A; Spaic T; Van Uum SH
    J Oncol; 2016; 2016():6496750. PubMed ID: 26977148
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism.
    Ringel MD; Ladenson PW
    J Clin Endocrinol Metab; 1996 May; 81(5):1724-5. PubMed ID: 8626823
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation.
    Molinaro E; Leboeuf R; Shue B; Martorella AJ; Fleisher M; Larson S; Tuttle RM
    Thyroid; 2009 Oct; 19(10):1035-41. PubMed ID: 19772430
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hyperkalemia develops in some thyroidectomized patients undergoing thyroid hormone withdrawal in preparation for radioactive iodine ablation for thyroid carcinoma.
    Horie I; Ando T; Imaizumi M; Usa T; Kawakami A
    Endocr Pract; 2015 May; 21(5):488-94. PubMed ID: 25667379
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial.
    Borget I; Bonastre J; Catargi B; Déandréis D; Zerdoud S; Rusu D; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Kelly A; Toubert ME; Leboulleux S; Journeau F; Benhamou E; Schlumberger M
    J Clin Oncol; 2015 Sep; 33(26):2885-92. PubMed ID: 26240230
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Interrupted 131I Procedures for Patients With Differentiated Thyroid Cancer: Comparing Thyroxine Withdrawal With Recombinant Thyrotropin Preparation Techniques.
    Karls S; Abikhzer G; Tamilia M; Probst S
    Clin Nucl Med; 2017 Apr; 42(4):247-249. PubMed ID: 28166158
    [TBL] [Abstract][Full Text] [Related]  

  • 74. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of renal function and demographic/anthropomorphic variables on peak thyrotropin after recombinant human thyrotropin stimulation: a stepwise forward multiple-regression analysis.
    Hautzel H; Pisar E; Lindner D; Schott M; Grandt R; Müller HW
    Thyroid; 2013 Jun; 23(6):662-70. PubMed ID: 23136932
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal.
    Vallejo Casas JA; Mena Bares LM; Gálvez Moreno MA; Moreno Ortega E; Marlowe RJ; Maza Muret FR; Albalá González MD
    Q J Nucl Med Mol Imaging; 2016 Jun; 60(2):163-71. PubMed ID: 26563902
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reversible renal insufficiency attributable to thyroid hormone withdrawal in a patient with type 2 diabetes mellitus.
    Bernet VJ
    Endocr Pract; 2004; 10(4):339-44. PubMed ID: 15760778
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
    Podoba J
    Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recombinant human thyroid-stimulating hormone-aided remnant ablation achieves a response to treatment comparable to that with thyroid hormone withdrawal in patients with clinically relevant lymph node metastases.
    Pitoia F; Abelleira E; Cross G
    Eur Thyroid J; 2014 Dec; 3(4):264-71. PubMed ID: 25759804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.